Drug Overview
Capmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR). C-MET is a receptor tyrosine kinase, and abnormal activation in cancer can trigger tumor growth, angiogenesis, and metastasis. As a result, patients with aberrant c-MET activity typically have poor prognosis, aggressive disease, and shortened survival. Capmatinib selectively binds to c-MET, thereby disrupting c-MET signaling pathways. This can induce cell death in tumor cells with high c-MET amplification.
Capmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR). C-MET is a receptor tyrosine kinase, and abnormal activation in cancer can trigger tumor growth, angiogenesis, and metastasis. As a result, patients with aberrant c-MET activity typically have poor prognosis, aggressive disease, and shortened survival. Capmatinib selectively binds to c-MET, thereby disrupting c-MET signaling pathways. This can induce cell death in tumor cells with high c-MET amplification.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
